Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in M…

Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first ...
Nasdaq

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission ...
TipRanks on MSN

Alpha Tau Medical unveils strong pancreatic cancer Alpha DaRT data ahead of ASCO GI 2026

An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 6, 2026, Alpha Tau Medical reported final results from its ...
Seeking Alpha

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (DRTS) ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha ...
Nasdaq

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

– Up to 87% of newly diagnosed pancreatic cancer patients are considered inoperable at diagnosis and face a dismal prognosis, with limited benefit from existing therapies – – This pilot study is a key ...
All Penny Stocks (English) on MSN

Throwing precision darts: The company leading next evolution of cancer radiation

Radiation therapy has been a foundation of cancer care for more than a century. From early X-ray machines to today’s ...